Cannabidiol‐induced activation of the metallothionein pathway impedes anticancer effects of disulfiram and its metabolite CuET
Disulfiram (DSF), an established alcohol‐aversion drug, is a candidate for repurposing in cancer treatment. DSF’s antitumor activity is supported by preclinical studies, case reports, and small clinical trials; however, ongoing clinical trials of advanced‐stage cancer patients encounter variable res...
Main Authors: | Tereza Buchtova, Zdenek Skrott, Katarina Chroma, Jiri Rehulka, Petr Dzubak, Marian Hajduch, David Lukac, Stefanos Arampatzis, Jiri Bartek, Martin Mistrik |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-04-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.13114 |
Similar Items
-
Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics
by: Tereza Buchtova, et al.
Published: (2023-02-01) -
Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway
by: Dusana Majera, et al.
Published: (2020-02-01) -
Metallothionein Family Proteins as Regulators of Zinc Ions Synergistically Enhance the Anticancer Effect of Cannabidiol in Human Colorectal Cancer Cells
by: In-Seo Kwon, et al.
Published: (2023-11-01) -
Encephalopathy caused by disulfiram
by: R. Sant’Angelo, et al.
Published: (2021-04-01) -
Disulfiram reaction
by: Banjac Nada, et al.
Published: (2019-01-01)